Introduction Brukinsa (zanubrutinib) and Jaypirca (pirtobrutinib) are two targeted cancer therapies used to treat Chronic Lymphocytic Leukemia (CLL). Over the last decade, CLL has transitioned from chemotherapy to targeted therapies…